ImmunoGen

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

ImmunoGen reports successful 2022, eyes growth opportunities in 2023

ImmunoGen's strong 2022 performance, strategic partnerships, and positive market feedback set the stage for continued growth. While facing challenges in expenses and revenue targets, the company is well-positioned to capitalize on upcoming milestones and revenue streams.

ImmunoGen reports robust Q1 revenue, eyes growth opportunities

ImmunoGen's Q1 2023 earnings call showcased strong revenue performance
ELAHERE's market uptake and physician feedback remain positive
Operational challenges include increased expenses and regulatory evolution
Opportunities lie in resistance mechanisms study and program expansions

ImmunoGen reports strong Q2 revenue, focuses on Elahere growth

ImmunoGen's Q2 performance showed revenue growth and strong cash position
Elahere's success in trials and sales presents growth opportunities
Challenges include managing expenses and competition in the market
Opportunities lie in R&D investments, market expansion, and guideline updates

ImmunoGen reports robust Q3 earnings, eyes global expansion opportunities

ImmunoGen's strong financial performance and ELAHERE's success highlight a promising quarter.
Challenges include late responses in data sets and understanding the FR alpha and CDH overlap.
Opportunities lie in providing future revenue guidance, expanding globally, and exploring new molecules.
Overall, ImmunoGen's focus on ELAHERE's growth and strategic initiatives position it well for the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops therapeutics for the treatment of cancer using its Targeted Antibody Payload (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent. Its products include Trastuzumab-DM1, a Phase II clinical trial product for the treatment of metastatic breast cancer; IMGN901, a Phase I clinical trial product to treat hematological malignancies, including multiple myeloma, small-cell lung cancer, Merkel cell carcinoma, and other cancers of neuroendocrine origin; SAR3419, a Phase I clinical trial product for the treatment of B-cell hematological malignancies, including non-Hodgkin's lymphoma; and IMGN388 and BIIB015, which are in Phase I clinical trials for the treatment of solid tumors. The company's products also comprise BT-062, a Phase I clinical trial product targeting multiple myeloma; SAR566658, a preclinical trail product for the treatment of breast, ovarian, and other solid tumors; SAR650984, a preclinical trail product to treat hematological malignancies; and TAP and other compounds. It has licensing or collaboration agreements with sanofi-aventis; Genentech, Inc.; Biotest AG; Bayer HealthCare AG; Biogen Idec; Amgen, Inc.; Centocor, Inc.; Cytovance Biologics LLC; Laureate Pharma, Inc.; BioInvent International AB; Diosynth RTP, Inc.; and Societa Italiana Corticosteroidi S.r.l. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.

ImmunoGen's (IMGN) third-quarter 2023 earnings and revenues surpass estimates, driven by strong adoption of its sole-marketed drug Elahere. The company reiterates its revenue guidance.

ImmunoGen (IMGN) Q3 Earnings Beat, Elahere Drives Revenues

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will participate in a fireside chat at the upcoming Jefferies London Healthcare Conference. The presentation is scheduled for November 15, 2023 at 9:30 am GMT / 4:30 am ET. A webcast of the presentation will be accessible through the “Investors and Media” section of the Company's website, www.immunogen.c.

ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies London Healthcare Conference

ImmunoGen, Inc. (NASDAQ:IMGN ) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Anabel Chan - Head, IR Mark Enyedy - President, CEO & Director Isabel Kalofonos - SVP & Chief Commercial Officer Lauren White - SVP & CFO Michael Vasconcelles - Chief Medical Officer Conference Call Participants John Newman - Canaccord Genuity Michael Schmidt - Guggenheim Securities Etzer Darout - BMO Capital Markets Dingding Shi - Jefferies Peter Lawson - Barclays Bank Boris Peaker - TD Cowen Asthika Goonewardene - Truist Securities Operator Good morning, ladies and gentlemen, and welcome to ImmunoGen's Third Quarter 2023 Financial and Operating Results Conference Call. Today's conference is being recorded.

ImmunoGen, Inc. (IMGN) Q3 2023 Earnings Call Transcript

ImmunoGen (IMGN) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.31 per share a year ago.

ImmunoGen (IMGN) Q3 Earnings and Revenues Top Estimates

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2023. “Building on the momentum generated in the first half of 2023, we delivered a strong third quarter highlighted by significant ELAHERE revenue growth and the achievement of key operational milestones,” said Mark Enyedy,.

ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results

ImmunoGen, Inc.'s marketing authorization application for ELAHERE, a cancer therapy, has been accepted by the EMA. Rumors suggest that large European pharma companies, including GSK, Sanofi, or Merck, may be interested in ImmunoGen. ImmunoGen has an approved drug, a modest pipeline with a catalyst upcoming, and a market cap of around $3.6 billion, making it an attractive target for acquisition.

Analyzing The Acquisition Potential Of ImmunoGen

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for mirvetuximab soravtansine (ELAHERE®) for the treatment of patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. "The acceptance of our.

ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

ImmunoGen (IMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ImmunoGen (IMGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

ImmunoGen (IMGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Strength Seen in ImmunoGen (IMGN): Can Its 11.7% Jump Turn into More Strength?

Fresenius Medical Care

Vericel

Several Zacks Medical sector stocks were recently added to the Zacks Rank #1 (Strong Buy) list over the last week and should be viable options for investors during economic uncertainty as healthcare is always essential.

Top Medical Stocks to Buy Amid Recent Market Volatility

ACV Auctions

Affirm

Oscar Health

Electrameccanica

OSCR, IMGN, AFRM, ACVA and SOLO have been added to the Zacks Rank #1 (Strong Buy) List on October 20, 2023.

New Strong Buy Stocks for October 20th

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Operating Results.

ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2023 Operating Results

Catalyst Pharmaceuticals

Inari Medical

Invest in stocks such as Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN) and Inari Medical (NARI) for solid earnings acceleration.

3 Solid Stocks to Buy for Superb Earnings Acceleration

Kyndryl Holdings

Invest in stocks like Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN), Inari Medical (NARI) and Kyndryl Holdings (KD) for superb earnings acceleration.

4 Stocks That Exhibit Solid Earnings Acceleration

The mean of analysts' price targets for ImmunoGen (IMGN) points to a 49.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think ImmunoGen (IMGN) Could Surge 49.11%: Read This Before Placing a Bet

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced findings from two subset analyses of the Phase 3 confirmatory MIRASOL trial (GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of ELAHERE® (mirvetuximab soravtansine-gynx) compared to chemotherapy in patients with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC). The findings will be pr.

ELAHERE® Shows Overall and Progression-Free Survival Benefit Regardless of Prior PARPi Exposure or Prior Lines of Therapy in FRα-Positive Platinum-Resistant Ovarian Cancer

AppLovin Corp

Arlo Technologies Inc

Carvana

IonQ

MoonLake Immunotherapeutics

Riot Blockchain

Super Micro Computer

Nvidia stock has tripled, but it's not No. 1 in 2023.

These 8 Stocks Are Outperforming Nvidia In 2023

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer.

ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer

Yesterday, ImmunoGen, Inc. announced it has entered an exclusive licensing agreement with Takeda for the rights to develop and commercialize Mirvetuximab Soravtansine in the Japanese market. ImmunoGen's antibody drug conjugate - marketed and sold as Elahere -is indicated for platinum resistant ovarian cancer. The drug won accelerated approval in November last year - but outstanding data from its MIRASOL study virtually guarantees a full approval.

ImmunoGen: Takeda Swoops For Slice Of Elahere - Adding To Valuation Uncertainty?

Takeda Pharmaceutical

Shares of ImmunoGen Inc. IMGN, +1.45% jumped 1.7% in premarket trading Monday, after the Massachusetts-based drug maker announced a collaboration with Takeda Pharmaceutical Co. Ltd. TAK, +0.59% 4502, +0.52% to commercialize its Elahere ovarian cancer treatment in Japan.

ImmunoGen stock jumps after licensing deal with Japan's Takeda Pharmaceutical

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in Japan.

ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in Japan

Amgen

Exelixis

The world may be on the mend from the grip of the global pandemic, but the consistent drumbeat for medical innovation remains as unyielding as ever. Amid this backdrop, Biotech stocks present a beacon of hope for humanity and a compelling avenue for savvy investors.

These Are the ONLY 3 Biotech Stocks to Consider in August 2023

Subscribers to Schaeffer's Event Trader  service scored a 272% profit with our  ImmunoGen, Inc. (NASDAQ:IMGN) August 17 put recommendation.

Options Bears Break Bank With Biotech Stock Puts

ImmunoGen's (IMGN) Q2 earnings show an encouraging adoption of the sole-marketed drug Elahere. The company, however, did not issue any product sales guidance for Elahere for 2023.

ImmunoGen (IMGN) Stock Down Despite Q2 Earnings & Sales Beat

ImmunoGen Inc. (NASDAQ:IMGN ) Q2 2023 Earnings Conference Call July 31, 2023 8:00 AM ET Company Participants Mark Enyedy - President, Chief Executive Officer Renee Lentini - Chief Financial Officer (interim), Chief Accounting Officer Isabel Kalofonos - Chief Commercial Officer Anna Berkenblit - Chief Medical Officer Michael Vasconcelles - Executive Vice President, Research and Development Anabel Chan - Head of Investor Relations Conference Call Participants John Newman - Canaccord Genuity Michael Schmidt - Guggenheim Peter Lawson - Barclays Etzer Darout - BMO Capital Markets Boris Peaker - Cowen Andy Hsieh - William Blair Kelly Shi - Jefferies Swayampakula Ramakanth - HC Wainwright Asthika Goonewardene - Truist Joe Catanzaro - Piper Sandler Jonathan Chang - Leerink Partners Operator Good morning and welcome to ImmunoGen's second quarter 2023 financial and operating results conference call. Today's conference is being recorded.

News for ImmunoGen Stock (IMGN)